To include your compound in the COVID-19 Resource Center, submit it here.

Telatinib: Final Phase II data

Final data from the open-label, U.S. and Spanish Phase II TEL0805 trial in 39 patients showed that first-line treatment with twice-daily oral

Read the full 220 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE